6 analysts have expressed a variety of opinions on Pharming (NASDAQ:PHAR) over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table provides a quick ...
Across the recent three months, 4 analysts have shared their insights on Pharming (NASDAQ:PHAR), expressing a variety of opinions spanning from bullish to bearish. The table below summarizes their ...
Good morning or good afternoon, everyone, and welcome to our Q2 2025 earnings call. So I'm Fabrice Chouraqui, the CEO of Pharming, and I'll be joined on this call today by Steve Toor, our Chief ...
Shareholders in Pharming Group N.V. (AMS:PHARM) had a terrible week, as shares crashed 23% to €1.10 in the week since its latest first-quarter results. Pharming Group reported a serious miss, with ...
Second quarter 2024 total revenues increased by 35% to US$74.1 million, compared to the second quarter 2023, driven by strong RUCONEST® and Joenja® revenue growth RUCONEST® second quarter revenue ...
If approved, Joenja will be the first approved treatment in the U.S. for children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare primary immunodeficiency Supplemental ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results